Continuous Infusion Treatment with Pentoxifylline in Patients with Severe Peripheral Vascular Occlusive Disease

Angelides, N. S.
August 1986
Angiology;Aug1986, Vol. 37 Issue 8, p555
Academic Journal
The effect of continuous i.v. infusion of pentoxifylline, administering 1 200 mg/24 hours through 15 days, was studied in 22 patients (19 m, 3 f) with arterio-graphically confirmed extensive occlusion in the femoro-popIiteal segment, associated with marked intermittent claudication and rest pain of varying severity. The following parameters were used for the verification of the therapeutic response: Flow resistance factor (RF), pressure indices at rest (RPI) and after exercise (PPI) and recovery time (RT) assessed by means of ultrasonic Doppler technique; muscle and skin blood flow at rest and after exercise using 99m Technetium Clearance Technique (TC); toe skin temperature (TST) by electric thermometer; painfree walking distance (WD) assessed on treadmill (horizontal, 4 km/h); rest pain (RP) was assessed by a 4-step-relief-scale. There was an overall good response to treatment, the studied parameters showing the following changes: RE improved in 12/17 patients (= 70%); RT decreased in 14/22 patients (= 63%) RPI and PPI showed no change; TC (muscle) increased after exercise in 17/22 patients (= 77%); TC (skin) increased after exercise in 20/22 patients (= 90%); WD increased on average by 80% (from 115 m to 206 m); TS increased in 16 limbs; RP showed an overall relief. The results of this study indicate that the continuous infusion of pentoxifylline is safe and effective in improving the condition of patients with severe peripheral vascular disease.


Related Articles

  • Failure of Pentoxifylline for End-stage Peripheral Vascular Disease. Loyd, Robert G.; Prian, Gregory W.; Gomez, Henry; Laub, James; Mertz, George H. // Angiology;Apr1987, Vol. 38 Issue 4, p304 

    In this trial of pentoxifylline, 15 patients with end-stage peripheral vascular disease had symptoms severe enough to warrant operation, but surgery was contraindicated because of anatomically noncorrectable disease, serious medical problems, or refusal. Their mean age was sixty-six years. Each...

  • Functional Vascular Disorders: Treatment with Pentoxifylline. Neirotti, Massimo; Longo, Flavia; Molaschi, Mario; Macchione, Carmine; Pernigotti, Luigi // Angiology;Aug1987, Vol. 38 Issue 8, p575 

    A group of 11 female patients (mean age 33.7±8 years) with a clearly proven primary Raynaud's syndrome of up to five years' duration were subjected to a two-month oral treatment with 3 × 400 mg pentoxifylline per day. The following parameters were studied without and with exposure to cold...

  • Is cilostazol more effective than pentoxifylline in the treatment of symptoms of intermittent claudication? Weismantel, David // Journal of Family Practice;Feb2001, Vol. 50 Issue 2, p181 

    This article presents a study which examined the effectiveness of cilostazol over pentoxifylline in the treatment of symptoms of intermittent claudication. The study population is composed of patients with stable moderate to severe symptoms of intermittent claudication and confirmed peripheral...

  • pentoxifylline.  // Royal Society of Medicine: Medicines;2002, p431 

    This article presents information on pentoxifylline, a vasodilator drug which dilates the blood vessels of the extremities and can be used to treat peripheral vascular disease such as Raynaud's phenomenon. Administration is oral. Side effects include gastrointestinal disturbances, agitation and...

  • Pentoxifylline in the Treatment of Vascular Impotence--Case Reports. Allenby, Kent S.; Burris, James F.; Mroczek, William J. // Angiology;May1991, Vol. 42 Issue 5, p418 

    Vascular impotence is a common medical problem for which available therapies are limited. Three impotent patients observed in the authors' practice who were receiving pentoxifylline for treatment of claudication of the lower extremities spontaneously reported improved sexual function. A...

  • Effects of Pentoxifylline on Choroidal Blood Flow in Nonproliferative Diabetic Retinopathy. Sebag, Jerry; Mai Tang; Brown, Sharon; Sadun, Alfredo A.; Charles, M. Arthur // Angiology;Jun1994, Vol. 45 Issue 6, p429 

    Objective: Diminished blood flow plays an important role in the progression of diabetic retinopathy Since increased blood viscosity is a contributing factor to hypoperfusion, it was of interest to determine whether therapy intended to decrease blood viscosity and induce vasodilation could...

  • pentoxifylline.  // Davis's Drug Guide for Nurses, 10th edition;2007, p940 

    The article presents information on the drug pentoxifylline for nurses. This is a blood viscosity reducing agent used for management of symptomatic peripheral vascular disease. By inhibiting platelet aggregation and decreasing fibrinogen, the drug decreases blood viscosity. Pentoxifylline is...

  • Pentoxifylline Treatment in Patients with Occlusive Peripheral Arterial Disease. Circulatory Changes and Effects on Prostaglandin Synthesis. Poggesi, Loredana; Scarti, Luca; Boddi, Maria; Masolti, Giulio; Neri Serneri, Gian Gastone // Angiology;Sep1985, Vol. 36 Issue 9, p628 

    Pentoxifylline has recently been reported to stimulate in vitro the synthesis of prostacyclin. However it is not known so far whether the drug is able to stimulate prostacyclin synthesis in man also in vivo. In the present study the effects of pentoxifylline on prostaglandin synthesis and...

  • Platelet Resistance to Prostacyclin. Enhancement of the Antiaggregatory Effect of Prostacyclin by Pentoxifylline. Manrique, R. V.; Manrique, V. // Angiology;Feb1987 Part 1, Vol. 38 Issue 2, p101 

    With regard to existence of high prostacyclin (PGI2) levels during atheromatosis and thrombus formation, resistance of platelets to prostacyclin and its analogues seems to play an important pathophysiologic key role for the clarify- big of vasoocclusive phenomena. Platelet resistance to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics